The effect of sodium tanshinone IIA sulfonate on coronary microcirculation in patients with acute coronary syndrome: Randomized, double blind, controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800020340

Enrollment

Unknown

Registered

2018-12-25

Start date

2019-01-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome

Interventions

therapy group:Tanshinone IIA sodium sulfonate injection

control group:placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with acute non-ST-segment elevation myocardial infarction undergo PCI procedure; (2) aged 18 and 75 years old; (3) Patients who voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with acute ST-segment elevation myocardial infarction; (2) Cardiogenic shock; (3) severe heart failure (NYHA class IV, or left ventricular ejection fraction = 35%) or severe valvular heart disease; (4) Patients with severe blood, nervous system and malignant tumors have a life expectancy of less than 3 years; (5) severe liver and kidney dysfunction (ALT > 3 times the upper limit of normal and / or Cr level = 265umol/L); (6) active bleeding; (7) pregnant or lactating women; (8) Those who have participated in or are participating in other clinical trials in the past three months.

Design outcomes

Primary

Measure	Time frame
Corrected TIMI frame count;AUC of CK-MB;	—

Countries

China

Contacts

Public ContactXujie Zhao

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

jacket_chiu@163.com+86 15918747821

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026